Journal
OTOLARYNGOLOGY-HEAD AND NECK SURGERY
Volume 168, Issue 4, Pages 829-838Publisher
WILEY
DOI: 10.1002/ohn.171
Keywords
cholesteatoma; cholesteatoma staging; endoscopic ear surgery; recurrence; residual cholesteatoma
Categories
Ask authors/readers for more resources
This study aimed to evaluate the surgical outcomes of cholesteatoma treated with endoscopic ear surgery (EES) or a combined endoscopic-microscopic approach (cEMA) based on various classification and staging systems. The results showed that EES or cEMA is an effective treatment for middle ear cholesteatoma. The STAM classification and the EJS have prognostic value, with certain stages associated with better outcomes. Mastoid involvement is a risk factor for recurrence, while attic localization is associated with residual disease.
ObjectiveThe aim of the study is to evaluate cholesteatoma's surgical outcomes in patients treated with endoscopic ear surgery (EES) or a combined endoscopic-microscopic approach (cEMA) according to STAM, STAMCO, ChOLE, and EAONO/JOS system (EJS) classifications and staging. Study DesignRetrospective study. SettingMonocentric study in a tertiary referral center. MethodsOne-hundred sixty-eight patients who underwent EES or cEMA for cholesteatoma between 2010 and 2018 were classified according to the abovementioned classification and staging. Data on cholesteatoma's recurrence and residual rates were collected. Inferential statistical analysis was performed to evaluate surgical outcomes and the prognostic value of classifications and staging. ResultsThe recurrence rate was significantly lower in cholesteatomas classified in EJS stage 1 (2.6%) and STAM stage 1 (0%). A comparison of the different stages of the disease showed a significantly lower recurrence only for stage 1 versus the superior stages of both classifications. Involvement of mastoid bone was associated with a higher risk of recurrence (odds ratio [OR]: 4.12; p = .031). Attical involvement was associated with a higher risk of residual cholesteatoma (OR: 1.165; p = .046). ConclusionEES or cEMA represents an effective treatment for middle ear cholesteatoma. The STAM classification and the EJS have shown a prognostic value, with STAM 1 and EAONO-JOS 1 stages associated with a better prognosis. Mastoid involvement represents a risk factor for recurrence. Attic localization is associated with residual disease. Localization at difficult access sites did not implicate a higher risk for recurrence or residual. ChOLE classification, Ossicular chain status, and complication status did not provide prognostic information regarding recurrence or residual cholesteatoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available